Find clinical trials for Acute Myeloid Leukemia (AML) in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Hanyang, Seoul, KOR:
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Seoul, Korea, Republic of and 125 other locations
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 164 other locations
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Seoul, Korea, Republic of and 33 other locations
The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856...
Phase 1
Seoul, Korea, Republic of and 19 other locations
when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...
Phase 3
Seoul, Korea, Republic of and 108 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 160 other locations
inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...
Phase 1, Phase 2
Seoul, Korea, Republic of and 34 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Seoul, Korea, Republic of and 48 other locations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...
Phase 1
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 36 other locations
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...
Phase 1
Seoul, Korea, Republic of and 23 other locations
Clinical trials
Research sites
Resources
Legal